Roche to appeal against preliminary NICE no for Herceptin for metastatic gastric cancer
This article was originally published in Scrip
Roche says it will appeal against preliminary draft guidance from the National Institute for health and Clinical Excellence (NICE) in England and Wales that declines to recommend Roche's HER2-targeted Herceptin (trastuzumab) for treating metastatic gastric cancer patients on the NHS. NICE says it has doubts over the drug's capacity to extend life.
You may also be interested in...
No device-related warning letters were released by the US FDA the week of 24 November.
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.